0000947871-20-000145.txt : 20200225
0000947871-20-000145.hdr.sgml : 20200225
20200225171154
ACCESSION NUMBER: 0000947871-20-000145
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200114
FILED AS OF DATE: 20200225
DATE AS OF CHANGE: 20200225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chimovits Erez
CENTRAL INDEX KEY: 0001706399
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 20652024
MAIL ADDRESS:
STREET 1: P.O. BOX 4023
CITY: HERZLIYA PITUACH
STATE: L3
ZIP: 4614001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Novus Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
BUSINESS PHONE: 949-238-8090
MAIL ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
FORMER COMPANY:
FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070622
4
1
ownership.xml
X0306
4
2020-01-14
0
0001404281
Novus Therapeutics, Inc.
NVUS
0001706399
Chimovits Erez
C/O NOVUS THERAPEUTICS, INC.
19900 MACARTHUR BLVD, SUITE 550
IRVINE
CA
92612
1
0
1
0
Warrants to Purchase Common Stock
2020-01-14
4
S
0
646204
0.20
A
2019-05-02
2020-11-02
Common Stock
646204
0
I
See Footnotes
Warrants to Purchase Common Stock
2020-01-14
4
S
0
646204
0.20
A
2019-05-02
2024-05-02
Common Stock
646204
0
I
See Footnotes
The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.
Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.
/s/ Erez Chimovits
2020-02-25